PATENT LITIGATION

• PENDING: SVL v. Carson Design and Manufacturing Inc, et. al,0-21-cv-00619 (DMN). Defending mid-sized HVAC products manufacturer in patent infringement and unfair competition case.
• Donaldson Company, Inc. v. Baldwin Filters, Inc.,0-04-cv-02679 (DMN). Represented plaintiff in a patent infringement dispute between two competitors in the air filters market.

TRADE SECRETS LITIGATION

• PENDING: Mednet Solutions v. Veeva Systems, Inc., 0-2020-cv-02502 (DMN). Co-counsel representing plaintiff in a trade secret misappropriation case.

PHARMACEUTICAL/HATCH-WAXMAN LITIGATION

• Forest Labs, et al. v. Teva Pharmaceuticals USA, Inc., et al. Served as lead trial counsel representing world’s largest generic drug company in patent infringement dispute relating to generic company’s attempt to market generic version of $2.2B blockbuster Alzheimer’s drug Namenda XR before patent expiration. An analyst attending the trial reported that the Jeff’s cross examination of the brand company’s main expert witness “drew blood on almost every point.” After the trial was over, but before decision, the case settled favorably for the generic company under confidential terms.
• OSI Pharmaceuticals, Inc., Pfizer, Inc. And Genentech, Inc. V. Teva Pharmaceuticals USA, Inc., et al. On a team representing a pharmaceutical company against charges of infringement of compound, polymorph and method patents relating to erlotinib (Tarceva®) in a Paragraph IV Hatch-Waxman case. Client was offered a favorable settlement on the first day of trial.
• Hoffmann-La Roche v. Teva Pharmaceuticals USA, Inc. Lead trial counsel in a Paragraph IV Hatch-Waxman case representing a pharmaceutical company concerning their ANDA for capecitabine (Xeloda®). Challenged the infringement and validity of listed Orange Book patents; case settled on favorable terms on the eve of the trial.
  Purdue v. Teva Pharmaceuticals USA, Inc. Part of a team that secured a victory for a large pharmaceutical company in a patent infringement case before a US District Judge in the SDNY. Successfully argued that four of the plaintiff’s patents lacked novelty and/or were obvious; fifth patent was ruled invalid for indefiniteness. Client was able to secure favorable settlement.
• Celgene v. Teva Pharmaceuticals USA, Inc. Lead trial counsel in a Paragraph IV Hatch-Waxman case over its efforts to introduce a generic version of Focalin® (dexmethylphenidate) into the consumer market. Achieved a successful settlement for the defendant.
• Astra v. Kremers Urban Development Co. And Schwarz Pharma. Part of a team representing Kremers Urban Development Co. And Schwarz Pharma in support of their ANDA seeking permission to launch a generic version of Prilosec® onto the market. The drug was netting around $10 million per day. Achieved a successful decision for clients in multidistrict litigation, finding no infringement, and permitting clients to introduce a generic version of the drug.

PRO BONO LITIGATION

• Kathryn Eich et al. V. City of Burnsville. With co-counsel: sued city of Burnsville, Minnesota, on behalf of resident of a Burnsville-manufactured home park because of the city’s enforcement of property maintenance code in the park. The city subsequently changed its code due to the lawsuit.

OTHER LITIGATION

• Annette Nawls v. Timothy Scott McCaffrey. Represented a woman assaulted at Mystic Lake Casino while working as a food and beverage server at a private party. Sued perpetrator for assault, tried the case to a jury and won a judgment of over $300,000.